3P Biopharmaceuticals appoints Iker Portugal as Chief Financial Officer

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics incorporates a new member to the management team and appoints Iker Portugal as Chief Financial Officer.

Iker Portugal is an experienced financial manager and joins 3P Biopharmaceuticals with the aim of boosting the company´s growth plans.

Iker comes to 3P with more than 20 years of financial leadership experience. He started his career in 1996 in financial consulting and investment banking and over his extended career he has held a wide range of corporate financial responsibilities, including Investor Relations, Planning & Control or Capital Markets in companies such as the airline technology provider Amadeus, and CFO for the food & drink manufacturer JGC Group. Since mid-2019, and prior to joining 3P, Iker has been a consultant and investor in a Biotech start-up.

Iker graduated in Business and Economics from the University of Navarra, and he holds a Master´s Degree in Economics from the London School of Economics (LSE).

I come to 3P Biopharmaceuticals very excited about the opportunity. 3P is a fast-growing company in an expanding sector: Biotech. Therefore the opportunity for all of us is unique. The fact that our majority partner is Keensight Capital is definitely a plus, as it brings, on the one hand, the expertise of a large fund specialised in Healthcare, and also the capital support that will allow us to grow faster and take advantage of growth opportunities that I am sure will arise“, explained Portugal.

Dámaso Molero, CEO at 3P Biopharmaceuticals said: “We are very pleased to welcome Iker to 3P and incorporate such an experienced leader to our team. I am sure we will have interesting good news coming soon.

I hope that I can contribute to 3P from all my previous experiences and help my colleagues bring the company to a different stage. We are a team prepared for the journey and we keep adding resources to become a leading player in our sector“, added Portugal.

Therefore, with this new addition to the management team, 3P Biopharmaceuticals continues its growth plan and consolidates a competitive position as one of the leading CDMOs in Europe.

Related Content

BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1

Published: 15th November 2022
3P Bio will focus on the transfer of the production process as well as the cGMP manufacturing of the drug substance to be used in Phase I and II clinical trials. The novel drug could cure neurodegenerative diseases such as Amyotrophic Lateral Sclerosis.
Read more

3P Biopharmaceuticals awards the prize for the best Master’s Thesis (TFM)

Published: 3rd October 2022
At the closing of the fifth edition of the Master in Galenic Design and Manufacturing in the Pharmaceutical Industry of the University of Navarra.
Read more

3P Biopharmaceuticals among the 100 best companies to work for in Spain

Published: 27th September 2022
The prestigious ranking is based on an exhaustive questionnaire that Actualidad Económica prepares and publishes every year, and which seeks to evaluate and reward those companies whose human resources management makes them benchmarks.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.